GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Inventories, Raw Materials & Components

NRX Pharmaceuticals (STU:B1Q) Inventories, Raw Materials & Components : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Inventories, Raw Materials & Components?

NRX Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Mar. 2024 was €0.00 Mil.


NRX Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for NRX Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Inventories, Raw Materials & Components Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - - -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NRX Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


NRX Pharmaceuticals (STU:B1Q) Business Description

Industry
Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines